Table 1.
Correlation between CASC9 expression and clinicopathological features of UCB patients
| Parameters Total | Group | Total | CASC9 expression | P value | |
|---|---|---|---|---|---|
| High | Low | ||||
| Gender | Male | 79 (75%) | 58 (55%) | 21 (20%) | 0.759 |
| Female | 27 (25%) | 19 (18%) | 8 (8%) | ||
| Age (years) | < 60 | 37 (35%) | 27 (25%) | 10 (9%) | 0.956 |
| ≥ 60 | 69 (65%) | 50 (47%) | 19 (18%) | ||
| Tumor size (cm) | < 3 cm | 42 (40%) | 27 (25%) | 15 (14%) | 0.118 |
| ≥ 3 cm | 64 (60%) | 50 (47%) | 14 (13%) | ||
| Multiplicity | Single | 59 (56%) | 38 (36%) | 21 (20%) | 0.033 * |
| Multiple | 47 (44%) | 39 (37%) | 8 (8%) | ||
| Histological grade | L | 48 (45%) | 25 (24%) | 23 (22%) | 0.001 ** |
| H | 58 (55%) | 52 (49%) | 6 (6%) | ||
| Tumor stage T | Ta,T1 | 26 (25%) | 10 (9%) | 16 (15%) | 0.001 ** |
| T2-T4 | 80 (75%) | 67 (63%) | 13 (12%) | ||
| Lymph nodes metastasis | NO | 92 (87%) | 65 (61%) | 27 (25%) | 0.153 |
| YES | 14 (13%) | 13 (12%) | 1 (1%) | ||
*P < 0.05; **P < 0.01. P < 0.05 was considered significant (Chi-square test between 2 groups)